← All trials
NCT02768805
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- Jul 1, 2016
- Completion date
- Dec 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 900
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- MedicagoLead sponsor
- Centre de Recherche St-Louis, Quebec, CanadaOverall official - principal investigator
- Topstone Research, Toronto, CanadaOverall official - principal investigator
- McGill UniversityOverall official - principal investigator
- University of MontrealOverall official - principal investigator
- Regional Clinical ResearchOverall official - principal investigator
- Broward Research GroupOverall official - principal investigator
- MRA Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.